Objective: To compare the effects of continuous noncombined transdermal estradiol versus oral conjugated estrogen on serum sex hormone-binding globulin (SHBG) levels prior to and during the 10th and 22nd weeks of therapy in patients with surgical menopause. Study design: Open, comparative trial. Patients were consecutively assigned to three groups: group 1 (n=18) received continuous transdermal estradiol (0.050 mg/day), group 2 (n=18) continuous oral conjugated estrogens (0.625 mg/day), whereas group 3 (n=15) received no treatment. Serum SHBG levels were determined before treatment and after 10 and 22 weeks of treatment. Results: Serum SHBG increased significantly with oral conjugated estrogens at 10 (p0.05). Conclusion: Transdermal estroge...
Our purpose was to assess the effects of estrogen replacement therapy on plasma levels of nitric oxi...
Objective: To investigate the acute effects of transdermal E2 administration on nitric oxide {NO} pl...
Controversies about the safety of different postmenopausal hormone therapies (HTs) started 30 years ...
Objective: To compare the effects of continuous noncombined transdermal estradiol versus oral conjug...
Objective: To determine the long-term effects of estrogen replacement therapy on sex hormone binding...
Plasma sex hormone-binding globulin (SHBG) levels are important in the regulation of plasma free and...
Plasma sex hormone-binding globulin (SHBG) levels are important in the regulation of plasma free and...
Objective - To evaluate the effects on hormonal and metabolic variables and bone density of a transd...
Abstract- In a double blind, parallel-group, clinical trial, we compared the effects of conjugated e...
Objective. We evaluated the acute effects of low-dose oral estradiol and sequential progesterone on ...
Background: Data regarding the possible effects of estrogen on ghrelin secretion in humans are limit...
Objective: To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT...
Objective: The aim of this study was to compare hormone levels between women who became postmenopaus...
OBJECTIVE: To evaluate and compare the effects or oral and transdermal estrogen replacement therapy ...
OBJECTIVE: Since hormonal replacement therapy (HRT) affects plasma GH levels, the present study aime...
Our purpose was to assess the effects of estrogen replacement therapy on plasma levels of nitric oxi...
Objective: To investigate the acute effects of transdermal E2 administration on nitric oxide {NO} pl...
Controversies about the safety of different postmenopausal hormone therapies (HTs) started 30 years ...
Objective: To compare the effects of continuous noncombined transdermal estradiol versus oral conjug...
Objective: To determine the long-term effects of estrogen replacement therapy on sex hormone binding...
Plasma sex hormone-binding globulin (SHBG) levels are important in the regulation of plasma free and...
Plasma sex hormone-binding globulin (SHBG) levels are important in the regulation of plasma free and...
Objective - To evaluate the effects on hormonal and metabolic variables and bone density of a transd...
Abstract- In a double blind, parallel-group, clinical trial, we compared the effects of conjugated e...
Objective. We evaluated the acute effects of low-dose oral estradiol and sequential progesterone on ...
Background: Data regarding the possible effects of estrogen on ghrelin secretion in humans are limit...
Objective: To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT...
Objective: The aim of this study was to compare hormone levels between women who became postmenopaus...
OBJECTIVE: To evaluate and compare the effects or oral and transdermal estrogen replacement therapy ...
OBJECTIVE: Since hormonal replacement therapy (HRT) affects plasma GH levels, the present study aime...
Our purpose was to assess the effects of estrogen replacement therapy on plasma levels of nitric oxi...
Objective: To investigate the acute effects of transdermal E2 administration on nitric oxide {NO} pl...
Controversies about the safety of different postmenopausal hormone therapies (HTs) started 30 years ...